

Request for Proposals

Landscape Analysis of Breast Diagnostic Imaging Coverage and Cost by Health Insurance Type

Date Issued: June 5, 2018

Closing Date: July 6, 2018

Background

Susan G. Komen is seeking proposals from firms and/or individuals to conduct an analysis of coverage and cost for breast diagnostic imaging (mammography, ultrasound, magnetic resonance imaging) in different health insurance types – Medicare, Medicaid, and private coverage. Diagnostic imaging is used to check for breast cancer after a lump or other sign or symptom of the disease has been found clinically or on screening mammography. Diagnostic imaging is also typically recommended for asymptomatic women that have undergone a lumpectomy followed by radiation therapy and those with a prior history of breast cancer.

Diagnostic imaging is typically more expensive than a screening mammography. As a result, patients are often burdened with co-pays and other cost-sharing when receiving diagnostic imaging, unlike with screening mammograms which are fully covered by Medicare and most private plans.

For women who receive abnormal results on a screening mammogram, reducing out-of-pocket costs for diagnostic imaging would improve access and utilization, and allow more timely diagnosis and treatment of breast cancer.

This analysis should define the problem in all health insurance types and assess potential public policy solutions. We seek data to supplement stories from women who have faced this problem.

The deadline to submit proposals is July 6, 2018. Please submit proposals by email to Molly Guthrie at mguthrie@komen.org.

Objectives and Deliverables

Komen continues to conduct research and policy analysis on the best method to address this issue via legislative and/or regulatory efforts. The results of the analysis will be used to strategize efforts at the federal and state levels.

The objectives of the study include the following:

- Provide informative, state-specific and national aggregate data, related to breast diagnostic imaging (mammography, ultrasound, magnetic resonance imaging) coverage and cost in different health insurance types – Medicare, Medicaid, and private plans
- Develop a cost-benefit analysis on the findings of screening mammography and diagnostic imaging coverage and how this influences the following:
 - Patient access
 - Out-of-pocket costs
 - Treatment delays/time to diagnosis



Once the analysis is complete, Komen will receive a report that summarizes findings to be shared with Komen staff, Affiliates, consultants, and other key stakeholders. The report should be comprehensive and include information on each of the diagnostic imaging tests, insurance types being analyzed, and findings by state. Additionally, an executive summary should be provided.

Project Timeline

The expectation is that the research study will be conducted over four to five months as per the timeline below:

Contract Start – August 1, 2018

Preliminary Draft Report – October 1, 2018

Final Report – December 1, 2018

Contract End – December 31, 2018

Submission Requirements

All proposals submitted in response to this Request for Proposals must include the following:

- A general overview of the services offered by your organization, as well as a description of your organization's qualifications and capacity to provide the services outlined
- A description of your proposed approach to the evaluation, including the implementation
- A preliminary project timeline, budget and milestones for the duration of the evaluation project

About Susan G. Komen

In 1980, Nancy G. Brinker promised her dying sister, Susan, that she would do everything in her power to end breast cancer forever. In 1982, that promise became the Susan G. Komen® organization and the beginning of a global movement. What was started with \$200 and a shoebox full of potential donor names has now grown into the world's largest nonprofit source of funding for the fight against breast cancer. To date, we've invested more than \$2.9 billion in groundbreaking research, community health outreach, advocacy and programs in more than 60 countries. Our efforts have helped reduce deaths from breast cancer by 39 percent between 1989-2015 and we won't stop until our promise is fulfilled.

Komen is also the world's largest grassroots network of breast cancer survivors and advocates. In order to achieve our mission, we believe that scientific progress and connection to care must be complemented by sound public policy and advocacy. Through government action, broad, systemic, lasting change can be made in the fight against breast cancer. This means that Komen—as a patient advocacy organization with first-hand knowledge of how breast cancer touches local communities—must engage policymakers and government as partners in our efforts to end breast cancer forever.